Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duvoglustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 6/20 | 1.00 |
| ▸ | GLA known ✓ | P06280 | 4/20 | 1.00 |
| ▸ | FUCA1 | P04066 | 4/20 | 1.00 |
| ▸ | MGAM | O43451 | 4/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 3/20 | 1.00 |
| ▸ | SI | P14410 | 3/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | GBA1 | P04062 | 2/20 | 1.00 |
| ▸ | LCT | P09848 | 2/20 | 1.00 |
| ▸ | GBA3 | Q9H227 | 2/20 | 1.00 |
| ▸ | MAN2B1 | O00754 | 1/20 | 1.00 |
| ▸ | MAN2B2 | Q9Y2E5 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | TREH | O43280 | 1/20 | 1.00 |
| ▸ | GANAB | Q14697 | 1/20 | 1.00 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duvoglustat SCHEMBL13298786 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL4619759 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL15896653 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL142573 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL10028910 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL12269503 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL24518227 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL2163281 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL13061461 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL21104989 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381164-A1 | Methods Of Treating Fabry Patients Having Renal Impairment | AMICUS THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230220320-A1 | Method For Capturing And Purification Of Biologics | AMICUS THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| EP-3957320-A1 | AUGMENTED ACID ALPHA-GLUCOSIDASE FOR THE TREATMENT OF POMPE DISEASE | Amicus Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20210393747-A1 | RECOMBINANT HUMAN ACID ALPHA-GLUCOSIDASE | AMICUS THERAPEUTICS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210228560-A1 | Combination of a Compound Having the Ability to Rearrange a Lysosomal Enzyme and Ambroxol and/or a Derivative of Ambroxol | CENTOGENE IP GMBH (DE) | 2021-07-29 | — | — | US | disclosed |
| EP-3397273-B1 | AUGMENTED ACID ALPHA-GLUCOSIDASE FOR THE TREATMENT OF POMPE DISEASE | AMICUS THERAPEUTICS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3782655-A1 | A METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN AND DERIVATIVES | Amicus Therapeutics, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10857212-B2 | Augmented acid alpha-glucosidase for the treatment of Pompe disease | AMICUS THERAPEUTICS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10813921-B2 | Method to predict response to pharmacological chaperone treatment of diseases | AMICUS THERAPEUTICS, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| EP-3470077-B1 | METHOD TO PREDICT RESPONSE TO PHARMACOLOGICAL CHAPERONE TREATMENT OF DISEASES | AMICUS THERAPEUTICS INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
| US-20110212996-A1 | METHOD TO PREDICT RESPONSE TO PHARMACOLOGICAL CHAPERONE TREATMENT OF DISEASES | AMICUS THERAPEUTICS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20110189710-A1 | TREATMENT OF POMPE DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARkERS | AMICUS THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110152319-A1 | METHOD TO PREDICT RESPONSE TO PHARMACOLOGICAL CHAPERONE TREATMENT OF DISEASES | AMICUS THERAPEUTICS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110136151-A1 | ASSAYS FOR DIAGNOSING AND EVALUATING TREATMENT OPTIONS FOR POMPE DISEASE | AMICUS THERAPEUTICS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | SUMMIT CORPORATION PLC (GB) | 2011-01-20 | — | — | US | disclosed |
| WO-2009114679-A2 | TREATMENT OF POMPE DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARKERS | AMICUS THERAPEUTICS, INC (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009114712-A2 | ASSAYS FOR DIAGNOSING AND EVALUATING TREATMENT OPTIONS FOR POMPE DISEASE | AMICUS THERAPEUTICS, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009102895-A2 | METHOD TO PREDICT RESPONSE TO PHARMACOLOGICAL CHAPERONE TREATMENT OF DISEASES | AMICUS THERAPEUTICS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381164-A1 | Methods Of Treating Fabry Patients Having Renal Impairment | GAA, GLA, GBA1 | GAA 1/4885GLA 2/4885FUCA1 59/4885 |
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | GAA 1/4885GLA 13/4885FUCA1 17/4885 |
| US-20110152319-A1 | METHOD TO PREDICT RESPONSE TO PHARMACOLOGICAL CHAPERONE TREATMENT OF DISEASES | MAN2B1, GAA, GBA1 | GAA 2/4885GLA 12/4885FUCA1 24/4885 |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | GPI, GALE, HAVCR2 | GAA 107/4885GLA 496/4885FUCA1 83/4885 |
| US-20210228560-A1 | Combination of a Compound Having the Ability to Rearrange a Lysosomal Enzyme and Ambroxol and/or a Derivative of Ambroxol | CMA1, MAN2B1, GBA3 | GAA 13/4885GLA 45/4885FUCA1 113/4885 |
| US-20210393747-A1 | RECOMBINANT HUMAN ACID ALPHA-GLUCOSIDASE | GAA, MAN2B1, MAN2A1 | GAA 1/4885GLA 9/4885FUCA1 12/4885 |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | IRS1, SLC2A1, INSR | GAA 268/4885GLA 1234/4885FUCA1 1506/4885 |
| US-20110212996-A1 | METHOD TO PREDICT RESPONSE TO PHARMACOLOGICAL CHAPERONE TREATMENT OF DISEASES | MAN2B1, GAA, GBA1 | GAA 2/4885GLA 12/4885FUCA1 24/4885 |
| US-10857212-B2 | Augmented acid alpha-glucosidase for the treatment of Pompe disease | GAA, MAN2B1, MANBA | GAA 1/4885GLA 10/4885FUCA1 24/4885 |
| US-10813921-B2 | Method to predict response to pharmacological chaperone treatment of diseases | MAN2B1, GAA, GBA1 | GAA 2/4885GLA 12/4885FUCA1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.